Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting

Christensen, MC; Fagiolini, A; Florea, I; Loft, H; Cuomo, A; Goodwin, GM

Journal article

Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting

Abstract:: Background The Oxford Depression Questionnaire (ODQ) is a patient-reported scale for assessing emotional blunting in patients with major depressive disorder (MDD). This analysis was undertaken to further validate the scale in patients experiencing emotional blunting while receiving antidepressant treatment.
Methods Patients with MDD who experienced inadequate depressive-symptom resolution and emotional blunting on selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor monotherapy (adequate dose for ≥6 weeks) were switched to vortioxetine 10–20 mg/day. ODQ total scores were assessed excluding and including the “antidepressant-as-cause” domain (ODQ-20 and ODQ-26, respectively). Anchor- and distribution-based methods were used to determine the minimal clinically important difference in ODQ scores in terms of change from baseline to week 8 of antidepressant treatment.
Results After 8 weeks of vortioxetine treatment, the mean change in ODQ-20 and ODQ-26 scores from baseline was −24.8 and −30.1 points, respectively. Greater mean changes from baseline in ODQ-20 and ODQ-26 scores were seen in patients reporting no emotional blunting vs those still experiencing emotional blunting after 8 weeks of vortioxetine treatment (ODQ-20: −27.0 vs −22.6 points; ODQ-26: –32.8 vs –27.5 points, respectively). In patients considered clinically minimally improved (Clinical Global Impression–Improvement score, 3) after 8 weeks of vortioxetine treatment, respective mean (standard deviation) change in ODQ-20 and ODQ-26 score from baseline was −15.5 (18.1) and –20.0 (20.5) points.
Limitations Short study duration.
Conclusions These results provide further validation of the clinical utility of the ODQ for assessing emotional blunting in patients with MDD. The suggested minimal clinically important difference for change in ODQ-20 and ODQ-26 scores is 16 and 20 points, respectively, after 8 weeks of antidepressant treatment.
Trial registration ClinicalTrials.gov identifier: NCT03835715.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Christensen, M. C., Fagiolini, A., Florea, I., Loft, H., Cuomo, A., & Goodwin, G. M. (2021). Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting. Journal of Affective Disorders, 294, 924–931.

MLA Style

Christensen, MC, et al. “Validation of the Oxford Depression Questionnaire: Sensitivity to Change, Minimal Clinically Important Difference, and Response Threshold for the Assessment of Emotional Blunting.” Journal of Affective Disorders, vol. 294, 2021, pp. 924–31.

Chicago Style

Christensen, MC, A Fagiolini, I Florea, H Loft, A Cuomo, and GM Goodwin. 2021. “Validation of the Oxford Depression Questionnaire: Sensitivity to Change, Minimal Clinically Important Difference, and Response Threshold for the Assessment of Emotional Blunting.” Journal of Affective Disorders 294: 924–31.
Print